Prevalence of HIV Drug Resistance Mutations Among Treatment-Naive People Living with HIV in a Tertiary Care Center in India

Overview

Journal Am J Trop Med Hyg

Specialty Tropical Medicine

Date 2024 Mar 5

PMID 38442417

Authors

Shweta Srivastva

Jaya Chakravarty

Anurag Kumar Kushwaha

Affiliations

Soon will be listed here.

Abstract

India has the third-largest number of people living with HIV (PLHIV) in the world. A national program provides free access to standard uniform antiretroviral therapy. However, the program is not monitored by comprehensive drug resistance surveys. The aim of this study was to determine the prevalence of HIV drug resistance mutations (DRMs) among treatment-naive PLHIV in a large antiretroviral treatment center of the national program. This cross-sectional study was done in 2017 and involved 200 consecutive treatment-naive PLHIV. A target fragment of 1,306 bp in the reverse transcriptase and protease regions was amplified. Identification of mutations and drug resistance interpretation was done by HIV Genotypic Resistance Interpretation and International Antiviral Society-USA list. Sequencing was successful in 177 samples. The majority (98.8%; 175/177) belonged to subtype C. Nineteen of 177 patients (10.7%; 95% CI: 6.2%-15.3%) had at least one major DRM. The prevalence of non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations was 10.2% (18/177). The most frequent mutations were E138A/K, A98G, K103N, V179D, and K101H/E. The prevalence of nucleoside reverse transcriptase inhibitor (NRTI) mutations was 1.1% (2/177). None of the samples had major protease inhibitor resistance mutations. The prevalence of NNRTI mutations in this study was >10%, crossing the threshold recommended by the WHO to change the NNRTI-based first-line regimen to non-NNRTI based. In 2021, the national program replaced efavirenz with dolutegravir in the first-line regimen of tenofovir, lamivudine, and efavirenz. As the majority (64%) of PLHIV in India are accessing free ART from the national program, this study highlights the need for regular nationally representative drug resistance surveys for optimizing antiretroviral regimens in the program.

References

Mulu A, Lange T, Liebert U, Maier M . Clade homogeneity and Pol gene polymorphisms in chronically HIV-1 infected antiretroviral treatment naive patients after the roll out of ART in Ethiopia. BMC Infect Dis. 2014; 14:158. PMC: 3976149. DOI: 10.1186/1471-2334-14-158. View

Chaturbhuj D, Hingankar N, Srikantiah P, Garg R, Kabra S, Deshmukh P . Transmitted HIV drug resistance among HIV-infected voluntary counseling and testing centers (VCTC) clients in Mumbai, India. AIDS Res Hum Retroviruses. 2010; 26(8):927-32. DOI: 10.1089/aid.2010.0032. View

Levison J, Orrell C, Gallien S, Kuritzkes D, Fu N, Losina E . Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. PLoS One. 2012; 7(3):e32144. PMC: 3302781. DOI: 10.1371/journal.pone.0032144. View

Chauhan C, Lakshmi P, Sagar V, Sharma A, Arora S, Kumar R . Primary HIV Drug Resistance among Recently Infected Cases of HIV in North-West India. AIDS Res Treat. 2019; 2019:1525646. PMC: 6415312. DOI: 10.1155/2019/1525646. View

Gunthard H, Calvez V, Paredes R, Pillay D, Shafer R, Wensing A . Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society-USA Panel. Clin Infect Dis. 2018; 68(2):177-187. PMC: 6321850. DOI: 10.1093/cid/ciy463. View

Geretti A . Epidemiology of antiretroviral drug resistance in drug-naïve persons. Curr Opin Infect Dis. 2007; 20(1):22-32. DOI: 10.1097/QCO.0b013e328013caff. View

Azam M, Malik A, Rizvi M, Singh S, Gupta P, Rai A . Emergence of drug resistance-associated mutations in HIV-1 subtype C protease gene in north India. Virus Genes. 2013; 47(3):422-8. DOI: 10.1007/s11262-013-0961-8. View

Wheeler W, Ziebell R, Zabina H, Pieniazek D, Prejean J, Bodnar U . Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS. 2010; 24(8):1203-12. DOI: 10.1097/QAD.0b013e3283388742. View

Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P . Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999; 353(9171):2195-9. DOI: 10.1016/s0140-6736(98)12291-2. View

10.

Deshpande A, Recordon-Pinson P, Deshmukh R, Faure M, Jauvin V, Garrigue I . Molecular characterization of HIV type 1 isolates from untreated patients of Mumbai (Bombay), India, and detection of rare resistance mutations. AIDS Res Hum Retroviruses. 2004; 20(9):1032-5. DOI: 10.1089/aid.2004.20.1032. View

11.

Kiros M, Hailu Alemayehu D, Geberekidan E, Mihret A, Maier M, Abegaz W . Increased HIV-1 pretreatment drug resistance with consistent clade homogeneity among ART-naive HIV-1 infected individuals in Ethiopia. Retrovirology. 2020; 17(1):33. PMC: 7526103. DOI: 10.1186/s12977-020-00542-0. View

12.

Azam M, Malik A, Rizvi M, Rai A . Trends of drug-resistance-associated mutations in the reverse transcriptase gene of HIV type 1 isolates from North India. Arch Virol. 2013; 159(4):719-25. DOI: 10.1007/s00705-013-1889-y. View

13.

Arora S, Gupta S, Toor J, Singla A . Drug resistance-associated genotypic alterations in the pol gene of HIV type 1 isolates in ART-naive individuals in North India. AIDS Res Hum Retroviruses. 2008; 24(2):125-30. DOI: 10.1089/aid.2007.0156. View

14.

Sinha S, Ahmad H, Shekhar R, Kumar N, Dar L, Samantaray J . Prevalence of HIV Drug Resistance Mutations in HIV Type 1 Isolates in Antiretroviral Therapy Naïve Population from Northern India. AIDS Res Treat. 2012; 2012:905823. PMC: 3312221. DOI: 10.1155/2012/905823. View

15.

Deshpande A, Karki S, Recordon-Pinson P, Fleury H . Drug resistance mutations in HIV type 1 isolates from naive patients eligible for first line antiretroviral therapy in JJ Hospital, Mumbai, India. AIDS Res Hum Retroviruses. 2011; 27(12):1345-7. DOI: 10.1089/AID.2011.0066. View

16.

Kannangai R, David S, Sundaresan V, Sachithanandham J, Mani M, Abraham O . Frequency of transmitted drug resistance mutations among treatment-naïve HIV-1-infected individuals at a tertiary care centre in South India. Mol Diagn Ther. 2015; 19(5):273-5. DOI: 10.1007/s40291-015-0160-5. View

17.

Torre D, Tambini R . Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study. HIV Clin Trials. 2002; 3(1):1-8. DOI: 10.1310/FY66-NVWJ-3332-HW3C. View

18.

Spira S, Wainberg M, Loemba H, Turner D, Brenner B . Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother. 2003; 51(2):229-40. DOI: 10.1093/jac/dkg079. View

19.

Murillo W, de Rivera I, Parham L, Jovel E, Palou E, Karlsson A . Prevalence of drug resistance and importance of viral load measurements in Honduran HIV-infected patients failing antiretroviral treatment. HIV Med. 2009; 11(2):95-103. DOI: 10.1111/j.1468-1293.2009.00747.x. View

20.

Chakravarty J, Sundar S, Chourasia A, Singh P, Kurle S, Tripathy S . Outcome of patients on second line antiretroviral therapy under programmatic condition in India. BMC Infect Dis. 2015; 15:517. PMC: 4647630. DOI: 10.1186/s12879-015-1270-8. View